The post Bitcoin ETF Holdings Reach $1B as Abu Dhabi Funds Ramp Up appeared on BitcoinEthereumNews.com. Abu Dhabi-linked state investors have quietly amassed significantThe post Bitcoin ETF Holdings Reach $1B as Abu Dhabi Funds Ramp Up appeared on BitcoinEthereumNews.com. Abu Dhabi-linked state investors have quietly amassed significant

Bitcoin ETF Holdings Reach $1B as Abu Dhabi Funds Ramp Up

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Abu Dhabi-linked state investors have quietly amassed significant bitcoin etf holdings in BlackRock’s flagship fund, even as U.S. products face renewed selling pressure.

Abu Dhabi sovereign wealth pushes past $1.04 billion in U.S. Bitcoin exposure

According to fourth-quarter Form 13F filings with the U.S. Securities and Exchange Commission, Mubadala Investment Company reported holding 12,702,323 shares of BlackRock‘s spot Bitcoin ETF as of Dec. 31, 2025, valued at approximately $630.7 million.

A separate disclosure shows Al Warda Investments owned 8,218,712 shares in the same fund, worth roughly $408.1 million at year-end. Combined, the two Abu Dhabi entities controlled about 20.9 million shares with a total market value just over $1.04 billion, underscoring sustained sovereign participation in regulated U.S. Bitcoin products.

Together, these positions highlight how sovereign wealth capital from Abu Dhabi is leaning into U.S.-listed digital asset vehicles. However, the filings also show that this exposure is concentrated in a single BlackRock ETF rather than spread across the broader U.S. spot market.

Bitcoin ETF flows show renewed selling pressure

The growing sovereign allocation arrives as U.S. spot Bitcoin ETFs record fresh outflows. Data provider SoSoValue reported total daily net redemptions of $104.87 million in the latest session, even as overall U.S. spot ETF assets remained substantial at $85.52 billion.

Over the same period, Bitcoin traded around $67,753, reflecting ongoing price volatility into early 2026. Moreover, recent flow data for late January and February shows a choppy pattern, with several large redemption days punctuated by brief spikes of inflows across the product suite.

The recent mix of outflows and inflows suggests that some institutional and professional investors are tactically trading exposure. That said, the Abu Dhabi disclosures instead point to large, strategic positions that appear more aligned with a long-term allocation than with short-term trading of spot bitcoin etf flows.

Longer-term strategy behind state-backed allocations

The 13F reports reflect positions as of Dec. 31, 2025 and do not capture any portfolio changes that may have occurred in early 2026. However, the scale of the holdings indicates that major state-backed investors remain committed to U.S.-listed Bitcoin vehicles despite recent volatility in flows.

Industry observers note that such large allocations by Abu Dhabi could influence how other sovereign and institutional players, including rivals to Mubadala and Al Warda, approach digital asset exposure. Moreover, the visibility provided by SEC filings may encourage further scrutiny of sovereign wealth bitcoin allocations as the market matures.

In summary, while near-term Bitcoin ETF data shows renewed outflows and shifting sentiment, Abu Dhabi’s billion-dollar positions in BlackRock’s spot fund underscore how some of the world’s largest state investors are still anchoring capital in U.S.-regulated crypto products.

Source: https://en.cryptonomist.ch/2026/02/18/bitcoin-etf-holdings-abu-dhabi/

Market Opportunity
Union Logo
Union Price(UNION)
$0.0004905
$0.0004905$0.0004905
-3.42%
USD
Union (UNION) Live Price Chart

SPACEX(PRE) Launchpad

SPACEX(PRE) LaunchpadSPACEX(PRE) Launchpad

Register for a chance to win a free lucky draw

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin is poised for a reversal if ETF demand returns or a ceasefire occurs, potentially crushing short sellers in a massive price squeeze.
Share
Coin Telegraph2026/04/04 19:58
Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Inertia is the invisible tax on modern industrial throughput. Every millisecond a robotic arm spends decelerating, or waiting for high-frequency vibrations to settle
Share
Techbullion2026/04/02 18:25

RealStocks Now Live

RealStocks Now LiveRealStocks Now Live

Trade real U.S. stock via regulated brokerage